Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review

Continuous subcutaneous apomorphine infusion (CSAI) is one of the advanced therapies for Parkinson's disease (PD).

• Publication year

  2023

• Venue

  Movement Disorders Clinical Practice

• Publication date

  2023-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mdc3.13810PMID 37772305PMCID PMC10525070
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.

  2022cited by this paper
• Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study.

  2021cited by this paper
• Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review

  2021cited by this paper
• Early factors for predicting discontinuation to subcutaneous Apomorphine infusion in Parkinson's disease: A prospective analysis of the Thai Apomorphine Registry.

  2021cited by this paper
• Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions

  2021cited by this paper
• Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study

  2021cited by this paper
• Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis

  2021cited by this paper
• Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis

  2020cited by this paper
• Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance.

  2020cited by this paper
• Subcutaneous apomorphine infusion in advanced idiopathic Parkinson's disease and agranulocytosis: a case report.

  2020cited by this paper
• Does Apomorphine Have an Effect on Body Weight? An Observational Study

  2020cited by this paper
• Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease

  2020cited by this paper
• The long-term effect of continuous subcutaneous apomorphine infusions on camptocormia in Parkinson's disease.

  2020cited by this paper
• Loss of Awareness after Continuous Apomorphine Infusion Withdrawal in Parkinson’s Disease

  2020cited by this paper
• Cutaneous adverse drug reaction after continuous subcutaneous apomorphine infusion

  2020cited by this paper
• Continuous subcutaneous apomorphine infusion in Parkinson’s disease: causes of discontinuation and subsequent treatment strategies

  2019cited by this paper
• Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy.

  2019cited by this paper
• Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.

  2019cited by this paper
• Severe abdominal panniculitis in a patient treated with continuous subcutaneous apomorphine infusion.

  2019cited by this paper
• Continuous subcutaneous apomorphine in advanced Parkinson’s disease patients treated with deep brain stimulation

  2019cited by this paper
• EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease

  2019cited by this paper
• Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.

  2019cited by this paper
• Apomorphine: The Initial Indian Experience in Relation to Response Tests and Pumps

  2019cited by this paper
• Cutaneous adverse drug reaction after apomorphine infusion, possibly caused by a systemic type IV hypersensitivity reaction to sodium metabisulfite: Report of 2 cases

  2018cited by this paper
• Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.

  2018cited by this paper
• Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease

  2018cited by this paper
• Caregiver burden and its related factors in advanced Parkinson’s disease: data from the PREDICT study

  2018cited by this paper
• Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life.

  2018cited by this paper
• Long‐term adherence to apomorphine infusion in patients with Parkinson disease: a 10‐year observational study

  2017cited by this paper
• Fat necrosis and subcutaneous abscesses due to apomorphine.

  2017cited by this paper
• Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations.

  2017cited by this paper
• Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients

  2017cited by this paper
• Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.

  2017cited by this paper
• Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.

  2016cited by this paper
• Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.

  2016cited by this paper
• Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson’s Disease: The APO-NIGHT Study

  2016cited by this paper
• Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study

  2015cited by this paper
• Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease: Clinical Experience After 3 Years’ Follow-up

  2015cited by this paper
• Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

  2015cited by this paper
• EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease

  2015cited by this paper
• Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.

  2015cited by this paper
• Continuous perioperative apomorphine in deep brain stimulation surgery for Parkinson's disease

  2014cited by this paper
• Cost Effectiveness of Apomorphine in the Treatment of Advanced Parkinson Disease in the UK and Germany: Results from a Multicounty Decision Analytic Model

  2013cited by this paper
• Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome

  2013cited by this paper
• Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation

  2012cited by this paper
• Attempted suicide under high dose dopaminergic therapy including apomorphine

  2012cited by this paper
• Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation contraindications.

  2012cited by this paper
• Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment.

  2012cited by this paper
• Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect

  2011cited by this paper
• A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

  2011cited by this paper
• Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.

  2010influential reference
• The Effects of Apomorphine on Visual Perception in Patients With Parkinson Disease and Visual Hallucinations: A Pilot Study

  2009cited by this paper
• Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study

  2009cited by this paper
• Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations

  2009cited by this paper
• Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

  2008cited by this paper
• Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus

  2006cited by this paper
• Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease

  2005cited by this paper
• Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges

  2005cited by this paper
• Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease

  2004cited by this paper
• A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease

  2004cited by this paper
• Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

  2004cited by this paper
• Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson’s disease patients previously reliant on apomorphine

  2003cited by this paper
• Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease

  2003cited by this paper
• Apomorphine Infusion and the Long-Duration Response to Levodopa in Advanced Parkinson's Disease

  2003cited by this paper
• Levodopa‐induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two‐year, prospective follow‐up

  2002cited by this paper
• Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients

  2002cited by this paper
• Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results

  2001cited by this paper
• Apomorphine: An underutilized therapy for Parkinson's disease

  2000cited by this paper
• Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD

  2000cited by this paper
• Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome

  1999cited by this paper
• Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease

  1998cited by this paper
• Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up

  1998cited by this paper
• Apomorphine infusional therapy in parkinson's disease: Clinical utility and lack of tolerance

  1995cited by this paper
• Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years

  1993cited by this paper
• Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery.

  1992cited by this paper
• Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.

  1991cited by this paper
• Transient cardiac arrest during continuous intravenous infusion of apomorphine.

  1990cited by this paper
• Subcutaneous apomorphine in the treatment of Parkinson's disease.

  1990cited by this paper
• Severe oedema after subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Side-effects of subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Subcutaneous apomorphine in Parkinson's disease.

  1989cited by this paper
• Subcutaneous apomorphine for on-off oscillations in Parkinson's disease.

  1988cited by this paper
• Apomorphine infusion for motor fluctuations in Parkinson's disease.

  1987cited by this paper
• Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

  1979cited by this paper
• Apomorphine in Parkinson's disease.

  1951cited by this paper

• Advanced Therapeutics in Parkinson’s Disease: What’s New?

  2026cites this paper
• [Continuous Subcutaneous Apomorphine Infusion Therapy: Economic Impact in Spain].

  2026cites this paper
• Perioperative Management of Implantable Devices

  2025cites this paper
• Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations

  2025influential citation
• Apomorphine: past, present and future in Parkinson's disease and beyond.

  2025cites this paper
• A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations.

  2025cites this paper
• Gene therapy for Parkinson's disease: trials and technical advances.

  2025cites this paper
• Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study

  2025cites this paper
• Supports available for apomorphine management: How best to facilitate appropriate usage of apomorphine?

  2025cites this paper
• Surgical Treatments of Parkinson's Disease.

  2025cites this paper
• Efficacy and Safety of Twelve Anti‐Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta‐Analysis of Randomized Controlled Trials

  2025cites this paper
• Reply: “Improving the Study of Impulse Control Disorders in CSAI‐Treated Parkinson's Disease: Methodological and Interdisciplinary Directions”

  2025cites this paper
• Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis

  2025cites this paper
• Profile of People With Parkinson's Disease Treated With a Device‐Aided Therapy in Spain. A Comparative Multicenter Observational Study

  2025influential citation
• Subcutaneous Apomorphine Infusion Initiation Is Associated with Impulse Control Disorder Attenuation in Advanced Parkinson's Disease Patients: Insights from the French NS‐Park Cohort

  2025cites this paper
• Cognitive outcomes of infusion therapies in Parkinson's disease: A comprehensive systematic review.

  2025cites this paper
• Navigating the therapeutic landscape in advanced Parkinson’s disease: a comprehensive review from infusion therapies to stem cells

  2025cites this paper
• Personality and quality-of-life improvement after apomorphine infusion in Parkinson’s disease

  2024cites this paper
• Mechanism and therapeutic targets of the involvement of a novel lysosomal proton channel TMEM175 in Parkinson's disease.

  2024cites this paper
• How to Use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson's Disease

  2023cites this paper